Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells

  • Authors: Heui Sook Jeon, Mee Young Ahn, Ji Hye Park, Tae Hyung Kim, Pusoon Chun, Won Hee Kim, Jungsu Kim, Hyung Ryong Moon, Jee H. Jung, Hyung Sik Kim
  • View Affiliations

  • Published online on: Sunday, August 1, 2010
  • Pages: 419-428
  • DOI: 10.3892/ijo_00000690

Abstract

To investigate the anticancer effects of the novel hydroxamic acid-derived histone deacetylase (HDAC) inhibitor MHY218, its efficacy was compared to that of suberoylanilide hydroxamic acid (SAHA) in human ovarian cancer cells. The anticancer effects of MHY218 on cell viability, cell cycle regulation and apoptosis were investigated. In addition, MHY218 or SAHA was administered for 28 days in a tumor carcinomatosis model with SKOV-3 cells. MHY218 significantly reduced the expression of HDAC4 and HDAC7 in SKOV-3 cells. Similarly, MHY218 also inhibited total HDAC, HDAC1, HDAC4 and HDAC7 enzyme activity in a concentration-dependent manner. The anticancer effect of MHY218 (IC50, 3.2 µM) was more potent than SAHA (IC50, 3.9 µM) in suppressing the SKOV-3 cell viability. Moreover, MHY218 markedly increased expression of p21WAF1/CIP1, which acts as a cell cycle inhibitor. Cell cycle analysis showed that the high dose (5 µM) of MHY218 significantly increased the proportion of cells in the G2/M phase. In particular, MHY218 and SAHA significantly increased the sub-G1 population and the number of TUNEL-positive apoptotic cells compared with those in the untreated control. These results were confirmed by analysis of poly-ADP ribose polymerase (PARP), where MHY218 and SAHA increased the level of an 85-kDa fragment resulting from PARP cleavage as well as caspase-3 activity. Likewise, MHY218-induced apoptosis through caspase-3 activation was confirmed by the increase in the release of cytochrome c and Bax/Bcl-2 ratio. In an in vivo tumor carcinomatosis model, the growth of transplanted SKOV-3 cells was inhibited by 71% after treatment with MHY218 (10 mg/kg), whereas SAHA (25 mg/kg) suppressed growth by 48%. These results indicate that MHY218 is a potent HDAC inhibitor that targets regulating multiple aspects of cancer cell death and might have preclinical value in ovarian cancer chemotherapy, warranting further investigation.
Journal Cover

August 2010
Volume 37 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

2013 Impact Factor: 2.773
Ranked #30/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jeon, H., Ahn, M., Park, J., Kim, T., Chun, P., Kim, W., Kim, J., Moon, H., Jung, J., & Kim, H. (2010). Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells. International Journal of Oncology, 37(2), 419-428.
MLA
Jeon, Ahn, Park, Kim, Chun, Kim, Kim, Moon, Jung, and Hyung Kim. "Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells." International Journal of Oncology International Journal of Oncology 37.2 (2010): 419-428.
Chicago
Jeon, Ahn, Park, Kim, Chun, Kim, Kim, Moon, Jung, and Hyung Kim. "Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells." International Journal of Oncology International Journal of Oncology 37 no. 2 (2010): 419-428.